Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

Purpose : to study the level of LAG-3 expression on B-lymphocytes and feasibility using it as a marker for predicting response therapy in patients with chronic lymphocytic leukemia (CLL). Material Methods . The included 40 newly diagnosed CLL. All were divided into two groups: group I: Binet stage A, who did not receive II: C, received immunochemotherapy RB FCR regimes. According treatment regimen hematological therapy, 4 subgroups distinguished: IIA-RB, IIA-FCR, IIB-RB, IIB-FCR. control consisted 20 people matched age gender without cancer. immunophenotype, B-lymphocytes, expression, minimal residual disease II after 6th course initially determined all groups by flow cytometry. data evaluated Statistica 13.0. Results Compared group, was found CLL before treatment. higher C than stage. demonstrated differences different responses therapy. observed an unfavorable A good can be achieved at within 14.57 ± 0.66 % regardless regimen, 41.95 1.62 %. Conclusion initial used monitoring treatment, used.